Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

10/26/2020 | 06:51am EST
FILE PHOTO: Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal

FRANKFURT (Reuters) - Bayer agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses.

Germany's Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday.

The North Carolina-based takeover target, also known as AskBio, is trying to use the harmless adeno-associated virus as a delivery device to bring genetic repair kits against a range of diseases into the body.Drugs and farming pesticides maker Bayer needs to upgrade its drug development pipeline amid a weaker outlook for agricultural sales and as it seeks to finalise an $11 billion settlement over claims its Roundup weedkiller causes cancer.

Among AskBio's most advanced projects are early tests on volunteers of prospective treatments against Pompe disease - a rare genetic disease causing buildup of a sugar molecule inside cells - as well as against Parkinson's disease and congestive heart failure.

Bayer said the deal complements the 2019 acquisition of BlueRock Therapeutics, a developer of stem cell therapies, and underscores Bayer's intention to create a cell and gene therapy business.

AskBio, which was founded in 2001, and BlueRock will exchange information and collaborate but will each operate as independent entities, prompting a pledge from AskBio's five main owners, who are co-founders or key scientists, to remain with the firm.

"We are staying on board because of the unique structure that Bayer has provided ... We'll have the ability to make our science decisions," said Chief Executive Officer and co-founder Sheila Mikhail.

Investors TPG Capital and Vida Ventures are selling a minority stake in the company.

AskBio is also helping other companies with their gene therapy research and production and has licensed experimental drugs to external partners, which has financed much of its own drug development activities. Bayer or AskBio would not provide figures for such fee revenues.

A potential treatment of Duchenne Muscular Dystrophy, invented by AskBio is currently being developed in clinical trials by Pfizer and this month won fast track https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-fda-fast-track-designation-duchenne status from U.S. regulators.

Bayer in 2018 moved to lean more strongly on external firms to improve drug development, which analysts say needs a boost to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.

Credit Suisse was financial advisor while Baker McKenzie was legal counsel to Bayer. JP Morgan was financial advisor to AskBio, while Ropes & Gray was legal counsel.

(Reporting by Ludwig Burger; Editing by Frances Kerry)

By Ludwig Burger

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 2.26% 48.685 Delayed Quote.-34.61%
CREDIT SUISSE GROUP AG 3.86% 11.85 Delayed Quote.-12.93%
PFIZER INC. 0.31% 36.635 Delayed Quote.-6.79%
Latest news "Companies"
03:01pCITIZENS FINANCIAL GROUP, INC. : Declares Dividends on Preferred Stock
03:01pHUDSON : Announces “Celebrate Books and Booksellers”
03:01pCFTC Approves Transfer of Minneapolis Grain Exchange's Contract Market Designation in Connection with Acquisition by Miami International Holdings; Parties Target December 4, 2020 Closing
03:01pGlobal Operational Intelligence Market 2020-2024 | Technavio
03:01pBlack Friday iPhone X, XS & XS Max Cell Phone Deals 2020 Rated by The Consumer Post
03:01pKALEIDO BIOSCIENCES : to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
03:01pELI LILLY AND : Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference
03:01pECOLAB : Names Chris Roberts Executive Vice President and General Manager of Global Food and Beverage
03:01pFARMERS NATIONAL BANC CORP. : Declares Quarterly Cash Dividend
03:00pWhat's New In The Islands Of The Bahamas This Winter
Latest news "Companies"